38
Participants
Start Date
December 31, 2011
Primary Completion Date
September 3, 2019
Study Completion Date
February 1, 2020
Rituximab
Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
Iv Methylprednisolone
Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
peroral methylprednisolone and Methotrexate
Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg
MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg
Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal
Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal
Department of Radiology, Karolinska University Hospital, Stockholm
Sahlgrenska University Hospital
OTHER
Göteborg University
OTHER